Skip to content

Will Erectile Dysfunction Increase the Risk of Prostate Cancer

Erectile Dysfunction and the Future Risk of Prostate Cancer: a Population-based Longitudinal Follow-up Study With Concurrent Double Comparison Cohorts

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03009123
Acronym
EDtoPC
Enrollment
21558
Registered
2017-01-04
Start date
2016-01-31
Completion date
2017-05-06
Last updated
2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Keywords

cohort study, prostate cancer, population-based study, benign prostatic hypertrophy

Brief summary

The rationale for investigating the hypothesis that there is an association between erectile dysfunction (ED) and the subsequent development of prostate cancer is based on three assumptions: 1) baseline ED is common in most if not all of the cross-sectional studies in men with prostate cancer; 2) the development of ED and prostate cancer may have certain shared common risk factors; and 3) the use of testosterone for the treatment of ED has been suspected to be associated with prostate cancer development. Controversy exists over whether men with ED have an increased risk of subsequent prostate cancer. Few studies have evaluated the risk of developing prostate cancer for men with ED. The investigators, therefore, conducted a population-based longitudinal study with eight years' follow-up to examine this association and to evaluate the magnitude of the risk.

Interventions

OTHERErectile dysfunction

Patients with ED are considered belonging to the exposure group.

Sponsors

Asia University
CollaboratorOTHER
National Central University, Taiwan
CollaboratorOTHER
Kuang Tien General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
50 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* men 50 years and older with no pre-existing prostate cancer

Exclusion criteria

* less than 50 years old * pre-existing prostate cancer

Design outcomes

Primary

MeasureTime frame
Incident prostate cancerthrough study completion, up to 7 years

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026